期刊文献+

人LL-37与干扰素α2a密码子的优化及其在毕赤酵母中的融合表达

The Codon Optimization and Fused Expression of LL-37 and IFN-α2a in Pichia pastoris GS115
下载PDF
导出
摘要 通过密码子优化,在毕赤酵母中高效表达人LL-37与IFN-α2a融合蛋白。先按P.pastoris密码子偏好性对LL-37与IFN-α2a的原始密码子进行了改造,并在二者之间加上Gly Gly Gly Gly Ser的柔性连接接头,人工合成设计的新序列,最后通过p PIC9K载体将其整合入P.pastoris GS115的基因组,构建出重组菌株GS115LI。利用遗传霉素浓度梯度筛选出两株高拷贝的GS115LI1和GS115LI2菌株。对这两株菌经发酵诱导后的发酵液进行SDS-PAGE检测、抗病毒活性检测和抗菌活性检测,证明重组株既能够成功表达出LL-37与IFN-α2a的融合蛋白,而且该融合蛋白成功保留了抗菌肽与干扰素的功能活性。诱导发酵后,融合蛋白的产量可达到819.1 mg/L,经盐析、疏水层析和离子交换层析分离,可得到纯度达97%的融合蛋白产物,回收率可达到46.2%,纯化后产品的效价可达2.6×108 IU/mg。经过密码子优化后,成功实现在毕赤酵母中高效表达出既有LL-37抗菌活性又具有干扰素α2a活性的融合蛋白。 To express the fussed protein of human LL-37 and IFN-α2a inPichia pastoriswith codon optimization. Recording to the codon preference ofP. pastoris, the codons of LL-37 and IFN-α2a were optimized. A flexible linker of GlyGlyGlyGlySer was placed between LL-37 and IFN-α2a. The newly scheming DNA sequence was synthesized chemically.P. pastoris GS115LI was constructed by integrating the new gene into GS115 with help of plasmid pPIC9K. With the scanning of geneticin concentration ladder, two strains, named as GS115LI1 and GS115LI2, were gotten with high copy number. With SDS-PAGE detection, anti-virus activity detection and antimicrobial activity detection of broth, the results proved GS115LI1 and GS115LI2 not only expressed the fused proteins, but also maintained the activities of LL-37 and IFN-α2a respectively. After fermentation and induction of recombinant, the productivity of fusion protein was 819.1 mg/L. With salting out, hydrophobic chromatography and ionic exchange chromatography, the purity of fusion protein was 97%, recovery rate was 46.2% and the potency of IFN was 2.6×108 IU/mg. After codon optimization, the fused protein of human LL-37 and IFN-α2a was expressed effectively inP. pastroriswith antimicrobial activity of LL-37 and antifungus activity of IFN-α2a.
作者 张明杰
出处 《生物技术通报》 CAS CSCD 北大核心 2014年第11期206-213,共8页 Biotechnology Bulletin
基金 广东省重大科技专项(2011A080502011)
关键词 干扰素Α2A LL-37 融合 表达 IFN-α2a LL-37 Fused protein Expression
  • 相关文献

参考文献24

  • 1Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first-or second-line therapy in patients with metastatic renal cell cancer [ J ] . Journal of Clinical Oncology, 2007, 25 ( 22 ) : 3288-3295.
  • 2Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B [ J ] . New England Journal of Medicine, 2004, 351 ( 12 ) : 1206-1217.
  • 3Liu YJ. IPC : professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors [ J ] . Annu Rev Immunol, 2005, 23 : 275-306.
  • 4Vileek J. Novel interferons [ J ] . Nature Immunology, 2003, 4 ( 1 ): 8-9.
  • 5Fensterl V, Sen GC. Interferons and viral infections [ J ] . Biofactors, 2009, 35 ( 1 ) : 14-20.
  • 6De Veer MJ, Holko M, Frevel M, et al. Functional classification of interferon-stimulated genes identified using microarrays [ J ] .Journal of Leukocyte Biology, 2001, 69 ( 6 ) : 912-920.
  • 7Foster GR, Finter NB. Are all type I human interferons equivalent? [ J ] . Journal of Viral Hepatitis, 1998, 5 ( 3 ) : 143-152.
  • 8Mogensen KE, Lewerenz M, Reboul J, et al. The type I interferon receptor: structure, function, and evolution of a family business [ J ]. Journal of Interferon & Cytokine Research, 1999, 19 ( 10 ) : 1069- 1098.
  • 9Bell SJ, Fam CM, Chlipala EA, et al. Enhanced circulating half- life and antitumor activity of a site-specific pegylated interferon-ct protein therapeutic [ J ] . Bioconjugate Chemistry, 2007, 19 ( 1 ) : 299-305.
  • 10Jo YW, Youn YS, Lee SH, et al. Long-acting interferon-α 2a modified with a trimer-structured polyethylene glycol : Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics [ J ]. International Journal of Pharmaceutics, 2006, 309 ( 1 ) : 87-93.

二级参考文献39

  • 1奥斯伯F 布伦特R 金斯顿RE 等 颜子颖 王海林 编译.精编分子生物学实验指南[M].北京:科学出版社,1998.366-373.
  • 2Lehrer RI, Ganz T. Cathelicidins: a family of endogenous antimicrobial peptides [ J ]. Curr Opin Hemato1,2002 ,9 ( 1 ) : 18 - 22.
  • 3Gudmundsson GH, Agerberth B, Adeberg J, et al. The humangene FALL - 39 and processing of the cathlin precursor to the antimicrobial peptide LL - 37 in granulocytes [ J ]. Eur J biochem,1996, 238(2) : 325 -332.
  • 4Gudmundsson GH, Magnusson KP, Chowdhary BP, et al. Structure of the gene for porcine peptide antibiotic PR -39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL - 39 [ J ]. Proc Natl Acad SciUSA, 1995, 92:7085-7089.
  • 5Yang YX, Feng Yun, Wang BY, et al. PCR - based site - specific mutagensis of FALL -39 and its biologic activities[J]. Acta Pharmacological Sinica, 2004, 25(2) : 239 -245.
  • 6Oren Z, Lerman JC, Gudmundsson GH, et al. Structure and organization of the human antimicrobial peptide LL37 in phospholipid membranes: relevance to the molecular basis for its noncell- selective activity[J]. Biochem J, 1999, 341:501 -513.
  • 7Mark AF, Marek AK. A novel peptide - IgG conjugate, CAP18 106 - 138 - IgG, that binding and neutralizes endotoxin and kills Gram- negative bacteria[J]. Infectious Disease, 1997, 175:621.
  • 8Zhao CQ, Nguyen T, Boo LM, et al. RL - 37, an alpha - helical antimicrobial peptide of the rhesus monkey [ J ]. Antimicrob Agents Chemother, 2001,45 (10) : 2695 -2702.
  • 9Gutterman JU. Cytokine therapeutics: lessons frominterferon alpha, Proceedings of the National Academy of Sciences of the United States of America, 1994, 91(4): 1198-1205.
  • 10Garwala SS, Kirkwood JM. Potential uses of interferon alpha 2 as adjuvant therapy in cancer. Annals of surgical oncology, 1995, 2(4): 365-371.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部